Title |
The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease
|
---|---|
Published in |
Frontiers in Neuroscience, June 2017
|
DOI | 10.3389/fnins.2017.00317 |
Pubmed ID | |
Authors |
Simon C. Drew |
Abstract |
The "therapeutic chelation" approach to treating Alzheimer's disease (AD) evolved from the metals hypothesis, with the premise that small molecules can be designed to prevent transition metal-induced amyloid deposition and oxidative stress within the AD brain. Over more than 20 years, countless in vitro studies have been devoted to characterizing metal binding, its effect on Aβ aggregation, ROS production, and in vitro toxicity. Despite a lack of evidence for any clinical benefit, the conjecture that therapeutic chelation is an effective approach for treating AD remains widespread. Here, the author plays the devil's advocate, questioning the experimental evidence, the dogma, and the value of therapeutic chelation, with a major focus on copper ions. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 33% |
France | 1 | 33% |
Switzerland | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 95 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 15 | 16% |
Researcher | 13 | 14% |
Student > Master | 13 | 14% |
Student > Ph. D. Student | 7 | 7% |
Student > Doctoral Student | 4 | 4% |
Other | 16 | 17% |
Unknown | 27 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Chemistry | 21 | 22% |
Biochemistry, Genetics and Molecular Biology | 15 | 16% |
Medicine and Dentistry | 8 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
Agricultural and Biological Sciences | 3 | 3% |
Other | 13 | 14% |
Unknown | 31 | 33% |